EN DE
Watch Opus Genetics, Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Opus Genetics, Inc. (IRD) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Opus Genetics, Inc. stock $2.41, price $4.23, that is 43.0% below the price, quality 49 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

OG Opus Genetics, Inc. logo Thin data Nov 10, 2026

Opus Genetics, Inc.

IRD · US
Very expensive, weak quality

Our calculation puts a fair price 43% below what the stock costs today.

Quality 49/100
Insiders sold $10.7M (6M)
Revenue last quarter 74% below a year ago.
Fair value $2.41 · Strongly overvalued
Weak Growth (revenue 3y −29.1 %/yr in USD)
Negative free cash flow
Trails peers (1/6)
Narrow moat 30/100
Thin data
Estimate
Watch Opus Genetics, Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$6.38 $0.7100 Fair Value $2.41 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.7100 – $6.38 · fair‑value band $1.81 – $3.01 · the $4.23 price screens above the $2.41 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Opus Genetics in your weekly email

Every Wednesday you see whether Opus Genetics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders.

Show moreShow less

It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.

The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene.

In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy.

Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc. and changed its name to Opus Genetics, Inc. in November 2020. The company was founded in 2018 and is headquartered in Durham, North Carolina.

Stock analysis

Opus Genetics, Inc. (IRD) currently trades at $4.23, while our estimate is $2.41, 43% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $1.81 (bear) to $3.01 (bull), the price of $4.23 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Opus Genetics, Inc. reported revenue of $14.2M in FY2025 versus $589K in FY2021, a compound +121.6%/yr. Reported net income was −$49.6M in FY2025.

Key figures

Market cap $471M Small · P/S ratio 35.3 · EPS (TTM) $−1.27 · Return on equity −4,797% · Return on assets (EBIT) −62.9% (5-year average) · Operating margin −2,183% · Revenue (TTM) $9.9M · Revenue growth (YoY) −73.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 30 out of 100 (medium confidence).

What moves the price

The share trades about 30% below its 52-week high and 143% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −43%, IRD screens richer than that median.

Fair Value

Bear $1.81 Fair Value $2.41 Bull $3.01
Price $4.23 · Downside -43.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 49/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 13
How much profit the company makes from its sales and capital
Quality Growth 78
Are margins and returns getting better?
Cashflow 29
Do the profits arrive as real cash?
Financial strength 59
Debt, balance sheet and risk of trouble
Investment 99
Does it invest with discipline instead of growing at any price?
Low Volatility 38
How calm the share price moves, does not count
Price momentum 60
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 79
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 5 officers or directors sold shares worth $10.7M and none bought.

  • SaleGeorge MagrathChief Executive Officer, Director5× since Mar 16, 2026: 81,273 shares, avg. $4.30$349,488Nov 3, 2026
  • SaleRobert E. GagnonChief Financial Officer4× since Apr 23, 2026: 57,625 shares, avg. $4.17$240,351Oct 23, 2026
  • SaleBenjamin R YerxaPresident, Director3× since Apr 23, 2026: 48,088 shares, avg. $3.71$178,572Oct 23, 2026
  • SaleJoseph K SchachleChief Operating Officer4× since Mar 16, 2026: 17,827 shares, avg. $4.19$74,691Oct 23, 2026
  • SaleFoundation Fighting Blindness Retinal Degeneration FundDirector3× since Dec 9, 2025: 6,256,000 shares, avg. $3.00$18.8MSep 30, 2026
  • SaleAshwath JayagopalChief Scientific & Dev. Ofc.2× since Mar 16, 2026: 11,261 shares, avg. $5.17$58,184Apr 23, 2026
  • SaleRabourn Amy ZarembaHead of Fin. Quality Assurance2× since Mar 16, 2026: 4,457 shares, avg. $5.23$23,317Apr 23, 2026
  • BuyCam GallagherDirector164,000 shares at $1.97$323,890Dec 29, 2025

Plus 2 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+29.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−29.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3,854.8% (2021) → −271.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

IRD screens overvalued: fair value 43% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Opus Genetics, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 49 · Above median
Fair Value upside −43.0% · Bottom 25%
Profitability
Return on assets −98.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −73.8% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 30.70× · Priciest 25%
P/S (12 months) 47.80× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs IRD
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs IRD
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs IRD
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs IRD
argenx SE ARGX $971.55 $908.40 −7% vs IRD
CSL Limited CSL A$201.68 A$181.40 −10% vs IRD
Moderna, Inc MRNA $250.83 $158.70 −37% vs IRD
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs IRD
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs IRD
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs IRD

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Opus Genetics, Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Opus Genetics, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/IRD

Frequently asked questions

Is Opus Genetics, Inc. (IRD) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $2.41 versus a price of $4.23, about 43% lower (overvalued).
What is the fair value of IRD?
Our estimate for Opus Genetics, Inc. is $2.41 (as of Nov 10, 2026), built from audited fundamentals. The current price: $4.23.
What is the quality score of IRD?
Opus Genetics, Inc. has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Opus Genetics, Inc. (IRD)?
Our calculated price target is the estimate of $2.41 (as of Nov 10, 2026). Cautious scenario $1.81, optimistic scenario $3.01. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Opus Genetics, Inc. stock forecast for 2026?
Our estimate puts fair value at $2.41, about 43% lower versus a price of $4.23 (overvalued). Cautious scenario $1.81, optimistic scenario $3.01. The calculation is refreshed regularly with new filings.
What is the revenue of Opus Genetics, Inc. (IRD)?
Opus Genetics, Inc. reported trailing-twelve-month revenue of about $9.9M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Opus Genetics, Inc. (IRD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Opus Genetics, Inc. it is $2.41 per share (as of Nov 10, 2026), against a price of $4.23.
Is Opus Genetics, Inc. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, IRD trades above its calculated fair value: price $4.23, fair value $2.41, a gap of about −43% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IRD?
No. The price is what the market pays today ($4.23); the fair value is what the company's own numbers justify ($2.41). For Opus Genetics, Inc. the two are $1.82 per share apart. That gap is exactly why we show both numbers side by side.
How much is Opus Genetics, Inc. worth?
The market values Opus Genetics, Inc. at about $471M (market capitalisation, as of Nov 10, 2026). Per share that is $4.23; our models calculate a fair value of $2.41 per share.
What do the bullish and bearish scenarios say about IRD?
Our models span a range for Opus Genetics, Inc.: cautious scenario $1.81, base $2.41, optimistic $3.01 per share (as of Nov 10, 2026, price $4.23). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is IRD from its 52-week high?
Opus Genetics, Inc. trades at $4.23, about 30% below its 52-week high of $6.07 and 143% above the low of $1.74 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $2.41 is for.
Which stocks are comparable to Opus Genetics, Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Opus Genetics, Inc. stock attractive at the current price?
The data as of Nov 10, 2026: price $4.23, calculated fair value $2.41 (−43%), Quality Score 49/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Opus Genetics, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Opus Genetics, Inc. (IRD)?
The closing price on Nov 10, 2026 was $4.23. Our estimate is $2.41, about 43% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Opus Genetics, Inc. right now?
The price sits above even our optimistic bull case ($3.01). The favourable scenario is already priced in. Weak quality (49/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Opus Genetics, Inc.

How large is the market capitalisation of Opus Genetics, Inc. (IRD)?
The market capitalisation of Opus Genetics, Inc. is $471M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Opus Genetics, Inc. (IRD)?
The price-to-sales ratio of Opus Genetics, Inc. is 35.3 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Opus Genetics, Inc. (IRD)?
Earnings per share at Opus Genetics, Inc. are $−1.27. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Opus Genetics, Inc. (IRD)?
The return on equity (ROE) of Opus Genetics, Inc. is −4,797% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Opus Genetics, Inc. (IRD)?
On an EBIT basis the return on assets of Opus Genetics, Inc. is −62.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Opus Genetics, Inc. (IRD)?
The operating margin of Opus Genetics, Inc. is −2,183% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Opus Genetics, Inc. (IRD)?
Revenue at Opus Genetics, Inc. is growing −73.8% versus a year earlier (3y avg −29.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Opus Genetics, Inc. (IRD) generate?
The free cash flow of Opus Genetics, Inc. is −$35.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Opus Genetics, Inc. (IRD) hold?
Opus Genetics, Inc. holds more cash than debt, $45.1M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Opus Genetics, Inc. in the live analysis

One click puts Opus Genetics, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.